selective oral LTA4H metalloenzyme inhibitor

in multiple inflamm. Ph. II incl. colitis + NASH

1800 cmpd fragment screen + frag. merging

J. Med. Chem., Feb. 16, 2021

Novartis, Basel, CH


2. The Novartis LTA4H metalloenzyme inhibitor, LYS006, is a selective oral agent in multiple Ph. II studies to treat inflammatory diseases including ulcerative colitis and NASH. The starting points…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: